BACKGROUND: Fecal antibodies against bacterial products may directly reflect the interaction between luminal bacteria and mucosal immunity, and assays for these antibodies may be clinically useful in the diagnosis and differential diagnosis of Crohn's disease-like (CDL) condition of the pouch. AIMS: This study aims to evaluate stool and serum anti-Saccharomyces cerevisiae antibodies (ASCA) in normal and diseased pouches, to assess the correlation between ASCA levels and endoscopic disease activity, and to ascertain the diagnostic utility of ASCA for CDL of the pouch. METHODS: One hundred eighty-nine patients with ileal pouches were prospectively enrolled and corresponding serum and pouch aspirate samples were collected. Fecal and serum ASCA levels were measured with enzyme-linked immunosorbent assay in a blinded fashion. Statistical analysis was then conducted using the signed rank test, Spearman correlation coefficients, and analysis of variance. RESULTS: Forty-three patients (22.8 %) had irritable pouch syndrome or normal pouches, 74 (39.2 %) had pouchitis/cuffitis, 52 (27.5 %) had CDL, 9 (4.8 %) had familial adenomatous polyposis, and 11 (5.8 %) had surgical complications of the pouch. Receiver operating characteristic curves to distinguish CDL from other categories of pouch dysfunction had an area under the curve (AUC) of 0.608 for fecal ASCA and an AUC of 0.517 for serum ASCA. Neither fecal nor serum ASCA correlated with endoscopic disease activity scores. There was a significant difference in the mean values of fecal ASCA between inflammatory and fistulizing CDL (0.27 vs. 0.03 ELISA units/ml, P < 0.05). CONCLUSIONS: Fecal ASCA appears to be better than serum ASCA in differentiating CDL from other pouch disorders, although this distinction may be of limited clinical utility.
BACKGROUND: Fecal antibodies against bacterial products may directly reflect the interaction between luminal bacteria and mucosal immunity, and assays for these antibodies may be clinically useful in the diagnosis and differential diagnosis of Crohn's disease-like (CDL) condition of the pouch. AIMS: This study aims to evaluate stool and serum anti-Saccharomyces cerevisiae antibodies (ASCA) in normal and diseased pouches, to assess the correlation between ASCA levels and endoscopic disease activity, and to ascertain the diagnostic utility of ASCA for CDL of the pouch. METHODS: One hundred eighty-nine patients with ileal pouches were prospectively enrolled and corresponding serum and pouch aspirate samples were collected. Fecal and serum ASCA levels were measured with enzyme-linked immunosorbent assay in a blinded fashion. Statistical analysis was then conducted using the signed rank test, Spearman correlation coefficients, and analysis of variance. RESULTS: Forty-three patients (22.8 %) had irritable pouch syndrome or normal pouches, 74 (39.2 %) had pouchitis/cuffitis, 52 (27.5 %) had CDL, 9 (4.8 %) had familial adenomatous polyposis, and 11 (5.8 %) had surgical complications of the pouch. Receiver operating characteristic curves to distinguish CDL from other categories of pouch dysfunction had an area under the curve (AUC) of 0.608 for fecal ASCA and an AUC of 0.517 for serum ASCA. Neither fecal nor serum ASCA correlated with endoscopic disease activity scores. There was a significant difference in the mean values of fecal ASCA between inflammatory and fistulizing CDL (0.27 vs. 0.03 ELISA units/ml, P < 0.05). CONCLUSIONS: Fecal ASCA appears to be better than serum ASCA in differentiating CDL from other pouch disorders, although this distinction may be of limited clinical utility.
Authors: B Shen; J P Achkar; B A Lashner; A H Ormsby; F H Remzi; C L Bevins; A Brzezinski; R E Petras; V W Fazio Journal: Gastroenterology Date: 2001-08 Impact factor: 22.682
Authors: V Annese; A Piepoli; F Perri; G Lombardi; A Latiano; G Napolitano; G Corritore; P Vandewalle; D Poulain; J F Colombel; A Andriulli Journal: Aliment Pharmacol Ther Date: 2004-11-15 Impact factor: 8.171
Authors: B Sendid; J F Colombel; P M Jacquinot; C Faille; J Fruit; A Cortot; D Lucidarme; D Camus; D Poulain Journal: Clin Diagn Lab Immunol Date: 1996-03
Authors: Bo Shen; Victor W Fazio; Feza H Remzi; Ana E Bennett; Ian C Lavery; Rocio Lopez; Aaron Brezinski; Kerry K Sherman; Marlene L Bambrick; Bret A Lashner Journal: Dis Colon Rectum Date: 2007-09 Impact factor: 4.585
Authors: Genevieve B Melton; Victor W Fazio; Ravi P Kiran; Jin He; Ian C Lavery; Bo Shen; Jean-Paul Achkar; James M Church; Feza H Remzi Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Gil Y Melmed; Phillip R Fleshner; Ovunc Bardakcioglu; Andrew Ippoliti; Eric A Vasiliauskas; Konstantinos A Papadakis; Marla Dubinsky; Carol Landers; Jerome I Rotter; Stephan R Targan Journal: Dis Colon Rectum Date: 2007-12-18 Impact factor: 4.585